In contrast, the combination of ibrutinib and anti-PD-L1 delayed tumor growth, improved survival, and reduced lung metastasis in both breast tumor-bearing mice and colon tumor-bearing mice [154]. This evidence concerns the gene CD274 and neoplasm.